DYNAVAX / LYME DISEASE – READ-ACROSS VS VALNEVA
• DYNAVAX PROGRAM: Dynavax Technologies developing protein subunit Lyme vaccine + CpG 1018, preclinical, clinical entry targeted ~2027
• VALNEVA PROGRAM: Valneva lead asset VLA15, multivalent OspA-based Lyme vaccine, in late-stage clinical development with Pfizer
• TECH DIFFERENCE: Valneva uses alum-adjuvanted OspA antigens; Dynavax differentiates via TLR9 CpG adjuvant aimed at stronger, longer-lasting immunity
• RISK PROFILE: Valneva = near-term regulatory and execution risk; Dynavax = earlier-stage scientific and timeline risk, higher optionality
• COMMERCIAL READ-ACROSS: Advancing VLA15 de-risks Lyme vaccine demand, pricing, and payer acceptance, indirectly validating Dynavax’s opportunity
• STRATEGIC OPTION: Dynavax positioned as next-gen or follow-on entrant (durability, dosing, booster logic) rather than first-to-market
• INVESTOR TAKEAWAY: Valneva success would likely expand category valuation, benefiting Dynavax via platform credibility + long-dated upside
• VALNEVA PROGRAM: Valneva lead asset VLA15, multivalent OspA-based Lyme vaccine, in late-stage clinical development with Pfizer
• TECH DIFFERENCE: Valneva uses alum-adjuvanted OspA antigens; Dynavax differentiates via TLR9 CpG adjuvant aimed at stronger, longer-lasting immunity
• RISK PROFILE: Valneva = near-term regulatory and execution risk; Dynavax = earlier-stage scientific and timeline risk, higher optionality
• COMMERCIAL READ-ACROSS: Advancing VLA15 de-risks Lyme vaccine demand, pricing, and payer acceptance, indirectly validating Dynavax’s opportunity
• STRATEGIC OPTION: Dynavax positioned as next-gen or follow-on entrant (durability, dosing, booster logic) rather than first-to-market
• INVESTOR TAKEAWAY: Valneva success would likely expand category valuation, benefiting Dynavax via platform credibility + long-dated upside